Among the topics of health and medicine that are pervasive today is the increasing prevalence of antibiotic-resistant bacteria. Namely, resistance to even the most powerful antibiotics—in strains including methicillin-resistant Staphylococcus aureas (MRSA) and vancomycin-resistant Staphylococcus and enterococcus—are of grave concern. What many people don’t know is that prior to the advent of chemotherapeutic antibiotics such as penicillin and various sulfa derivatives as part of the pharmacologic repertoire in the early Twentieth century, prophylactic and therapeutic bacteriophage (phage) treatments as agents against bacterial infections were done, and some were purportedly successful. But the fact that phage are viruses that mediate killing of specific bacterial species, and do not target broad spectra of bacteria like their chemical counterparts, likely contributed to murky trial outcomes and largely to their abandonment as clinical antibacterial agents. Within the past decade, however, there have been isolated reports of clinical phage treatments being used in last-ditch approaches to ward off antibiotic-resistant bacterial infections, with many of them arising in patients battling cystic fibrosis and corresponding with successful outcomes. And as a result of an even more recent study, momentum seems to be gaining for the potential power of phage therapy, as engineered bacteriophages were used in 2018 to treat a 15-year-old cystic fibrosis patient with a disseminated drug-resistant Mycobacterium abscessus; this treatment also corresponded with a significantly improved clinical outcome. Please note that the language used above in describing these successful outcomes does not attribute directly to the phage treatments: even with these positive outcomes, there remains a lack of validated and adequately controlled clinical trials—and no FDA approval—for phage therapy. So, while the reported alleviation of symptoms for patients are suggestive that phage therapy could serve as an added weapon to the antibiotic arsenal, significant research must still be done to better understand its mechanistic basis within the patient—particularly since delivery of viruses and the immune response in humans poses different challenges than chemotherapeutics—to confirm its general efficacy, and validate its safety. But there is no doubt these efforts would be worth the significant reward of engaging a near century’s-old idea: to use bacteriophage to ward off bacterial infections, but today, to especially address those that are insensitive to chemical antibiotics.